Vivos Therapeutics, Inc. Stock Analysis & AI Score
Vivos Therapeutics, Inc. (VVOS) has an ST Score of 41.8 (C), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $2.13 price target (+1363.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Devices |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Vivos Therapeutics, Inc. (VVOS) has an ST Score of 41.8 (C), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $2.13 price target (+1363.9% upside).
- Strongest
- ForecastA
- Weakest
- MomentumF
All factor grades
- ForecastA
- GrowthB+
- ValuationC
- Financial StrengthC
- ProfitabilityD+
- MomentumF
- Piotroski3/9
Contact
VVOS stock: frequently asked questions
What is VVOS's ST Score?
Vivos Therapeutics, Inc. (VVOS) has an ST Score of 41.8 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is VVOS a buy, hold, or sell?
Analysts rate VVOS a Buy, with a price target of $2.13 (+1363.9% vs the current price). Our ST Score grades it C (41.8/100). The ST Score is a data-driven signal, not a recommendation.
What are VVOS's factor grades?
Valuation C, Profitability D+, Financial Strength C, Momentum F, Growth B+, Forecast A.
What is VVOS's valuation grade?
Vivos Therapeutics, Inc. (VVOS) earns a valuation grade of C, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is VVOS's growth grade?
Vivos Therapeutics, Inc. (VVOS) earns a growth grade of B+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is VVOS's profitability grade?
Vivos Therapeutics, Inc. (VVOS) earns a profitability grade of D+, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is VVOS's financial strength grade?
Vivos Therapeutics, Inc. (VVOS) earns a financial strength grade of C, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for VVOS?
The average analyst price target for Vivos Therapeutics, Inc. (VVOS) is $2.13 from 5 analysts, which is +1363.9% versus the recent price of $0.15.
What is VVOS's Piotroski score?
Vivos Therapeutics, Inc. (VVOS) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.